The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely with antiangiogenic agents. The study protocol intends to include ten patients per tumour entitity (n=40), treated either with Sorafenib (Nexavar), Bevacizumab (Avastin) or Sunitinib (Sutent), which are all approved antiangiogenic drugs in Austria in one of the cancer types defined above.
Conditions
Interventions
Trade Name: Sutent
Product Name: Sutent
Product Code: H-C-687
Pharmaceutical Form: Tablet
INN or Proposed INN: Sunitinib
Trade Name: Nexavar
Product Name: Nexavar
Pharmaceutical Form: Tablet
INN o
Sponsors
Medizinische Universität Innsbruck Innere Medizin V
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histological confirmed Tumor specimen RCC, HCC, CRC or NSCLC Measurable disease according to RECIST criteria Age: 18-80 years Antiangiogenic Monotherapy (Avastin, Nexavar or Sutent) WHO 0-2 Life expectancy of more than 3 months Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Prior or concurrent antitumor therapy (<3 weeks) Pregnant or lactating patients Preconditions in which MRI is contraindicated (claustrophopia, certain metal implants, others)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.;Secondary Objective: ;Primary end point(s): Evaluation of biomarker analyses | — |
Countries
Austria
Outcome results
None listed